newsfilter
← Latest News
PR Newswire·

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

  • Kuehn Law, PLLC is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential fiduciary duty breaches by officers & directors.
  • The federal securities lawsuit alleges insiders overstated the company's readiness to meet FDA manufacturing compliance requirements.
  • The suit claims regulatory prospects for the OLC NDA were also misrepresented.
  • Public statements regarding these matters are alleged to be materially false & misleading at all relevant times.
  • Shareholders who purchased UNCY prior to March 29, 2024, may contact Justin Kuehn, Esq. via email or phone to participate.
  • Kuehn Law covers all case costs & does not charge investor clients for representation.
  • Investors are urged to contact the firm immediately due to potential time limits on enforcing their rights.